Why Moderna Stock Plunged Today
Moderna (NASDAQ: MRNA) shares fell 9% on Tuesday as biotechnology tested whether its coronavirus vaccine would be effective against a highly contagious new strain of the virus. Investors and the world cheered when a Phase 3 clinical trial showed Moderna's vaccine candidate, mRNA-1273, is 94% effective against COVID-19 and 100% effective against severe forms of the disease. Moderna's share price nearly doubled after the drug maker released data from an interim analysis of the clinical trial in mid-November.
You should check here to buy the best price guaranteed products.
Report Reveals Wild History Of Woman Leading Firms Pushing 'Italygate' Election Conspiracy Theory
Sen. Ron Johnson, who stalled the passing of Juneteenth as a federal holiday, was booed at an event commemorating the day
Florida man allegedly pulls a gun on Starbucks employee over botched order, but not on just any employee
Americans are quitting their jobs at record pace, report says
Phil Mickelson doesn’t need a trophy to be the (second) best U.S. Open player of his generation
Rick Santorum speaks out on CNN firing, says decline of Trump news a factor